S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not an antagonist

Endocrinology

Volumn 142, Issue 9, 2001, Pages 3950-3963

  Bernichtein, Sophie ^a   Kinet, Sandrina ^a,b   Jeay, Sébastien ^a   Llovera, Marta ^a   Madern, Dominique ^c   Martial, Joseph A ^b   Kelly, Paul A ^a   Goffin, Vincent ^a  

^a INSERM   (France)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARTIC ACID; GLYCINE; JANUS KINASE; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; PROLACTIN; PROLACTIN DERIVATIVE; SERINE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOASSAY; BREAST TUMOR; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR CELL;

EID: 0034864156     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.142.9.8369     Document Type: Article

References (59)

1. Prolactin and its receptor: Actions, signal transduction pathways and phenotypes observed in prolactin receptor knockout mice
2. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene
3. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse
4. The prolactin/growth hormone receptor family
5. Prolactin and growth hormone receptors
6. Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen and related proteins in mammals
7. Binding in the growth hormone receptor complex
8. Involvement of prolactin in breast cancer: Redefining the molecular targets
9. Prolactin-induced proliferation of Nb2 cells involves tyrosine phosphorylation of the prolactin receptor and its associated tyrosine kinase JAK2
10. Jak2 activation and cell proliferation induced by antibody-mediated prolactin receptor dimerization
11. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response
12. Structural variants of prolactin: Occurence and physiological significance
13. Phosphorylated variant of bovine prolactin
14. Isolation and characterization of phosphorylated bovine prolactin
15. Phosphorylation of prolactin
16. Lack of correlation of distribution of prolactin (PRL) charge isoforms with induction of PRL storage
17. Phosphorylation of prolactin and growth hormone
18. Identification of the major site of rat prolactin phosphorylation as serine 177
19. Dephosphorylation of standard prolactin produces a more biologically active molecule: Evidence for antagonism between nonphosphorylated and phosphorylated prolactin in the stimulation of Nb2 cell proliferation
20. Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone
21. Biological activity of phosphorylated and dephosphorylated bovine prolactin
22. Bioactive recombinant methionyl bovine prolactin: Structure-function studies using site-specific mutagenesis
23. Rational design of potent antagonists to the human growth hormone receptor
24. Mechanism-based design of prolactin receptor antagonists
25. Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay
26. Biological properties of human prolactin analogs depend not only on global hormone affinity, but also on the relative affinities of both receptor binding sites
27. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation
28. Dissociation of Janus kinase 2 and signal transducer and activator of transcription 5 activation after treatment of Nb2 cells with a molecular mimic of phosphorylated prolactin
29. Should prolactin be reconsidered as a therapeutic target in human breast cancer?
30. Human prolactin: cDNA structural analysis and evolutionary comparisons
31. Evidence for a second receptor binding site on human prolactin
32. Bacterial production and purification of recombinant human prolactin
33. Alanine-scanning mutagenesis of human prolactin: Importance of the 58-74 region for bioactivity
34. Functional activity of the human prolactin receptor and its ligands
35. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
36. Evaluation of secondary structure of proteins from UV circular dichroism spectra using an unsupervised learning neural network
37. A new sensitive and specific bioassay for lactogenic hormones: Measurement of prolactin and growth hormone in human serum
38. Prolactin-stimulated growth of cell cultures established from malignant Nb rat lymphomas
39. The human growth hormone antagonist B2036 does not interact with the prolactin receptor
40. The addition of nine residues at the C-terminus of human prolactin drastically alters its biological properties
41. Prolactin variants
42. Characterization of lactogen receptor binding site 1 of human prolactin
43. Receptor-mediated mitogenic action of prolactin in a rat lymphoma cell line
44. G120R, a human growth hormone antagonist, shows zinc-dependent agonist and antagonist activity on Nb2 cells
45. Inhibition of lactogenic activities of ovine prolactin and human growth hormone (hGH) by a novel form of modified recombinant hGH
46. Site-directed mutations of human growth hormone that selectively modify its lactogenic activity and binding properties
47. Direct evidence that lactogenic hormones induce homodimerization of membrane-anchored prolactin receptor in intact Nb2-11C rat lymphoma cells
48. Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines
49. Receptor-mediated mitogenic action of prolactin in a rat lymphoma cell line
50. Receptor dimerization determines the effects of growth hormone in primary rat adipocytes and cultured human IM-9 lymphocytes
51. 694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription
52. Use of a model to understand prolactin and growth hormone specificities
53. Administration of unmodified prolactin (U-PRL) and a molecular mimic of phosphorylated prolactin (PP-PRL) during rat pregnancy provides evidence that the U-PRL:PP-PRL ratio is crucial to the normal development of pup tissues
54. Administration of human PRL mutant, S179D, markedly reduces the incidence of tumors when DU145 human prostate cancer cells are grown in nude mice
55. Central infusions of the recombinant human prolactin receptor antagonist, S179D-PRL, delay the onset of maternal behavior in steroid- primed, nulliparous female rats
56. Administration of a prolactin receptor antagonist to pregnant rats resulted in increased fetal intrathymic apoptosis and no γδ T cell seeding of the epidermis
57. Unmodified prolactin promotes ductal and lobulo-alveolar growth, while a molecular mimic of phosphorylated prolactin promotes lobuloalveolus formation and casein gene expression in the pregnant rat mammary gland
58. Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat
59. Osteoblasts are a new target for prolactin: Analysis of bone formation in prolactin receptor knockout mice